Görüntüleme
12
İndirme
2
Amaç: Santral retinal ven tıkanıklığı (SRVT) ve retinal ven dal tıkanıklığına (RVDT) bağlı oluşan maküler ödem (MÖ) tedavisinde deksametazon implantın altı aylık etkisini ve yan etkilerini değerlendirmek. Gereç: Göz Hastalıkları Kliniğinde SRVT (n=19) ve RVDT(n=18) sonucu oluşan MÖ nedeniyle tek doz intravitreal dexametazon implant ile tedavi edilen 37 hasta (37 göz) çalışmaya dahil edildi. Hastaların kayıtları retrospektif olarak incelendi. En az 6 ay boyunca, aylık olarak takip edilen hastalar çalışmaya dahil edildi. Başlangıç ve tedavi sonrası her kontrolde yapılmış olan; biyomikroskopik muayene bulguları, en iyi düzeltilmiş görme keskinliği (EDGK) düzeyi ve spektral domain optik koherens tomografi (OKT) ile santral maküler kalınlık (SMK) ölçümleri ve yan etkiler kaydedilerek değerlendirildi. Bulgular: RVDT olguları grup 1 (n=18), SRVT olguları grup 2 (n=19) olmak üzere hastalar 2 gruba ayrıldı. Tüm hastalarda tedavi sonrası EDGK 4. aya kadar anlamlı olarak artarken SMK değerleri anlamlı olarak azaldı (p<0.05). Tedavinin 4. ayından sonra ise EDGK değeri tedavi öncesine göre istatistiksel olarak farklı değildi. Maximum görme keskinliğindeki artış grup 2’ye kıyasla grup 1’de anlamlı olarak fazla idi. İki grup arasında ortalama SMK azalması açısından istatistiksel olarak anlamlı bir fark bulunmadı (p>0.05). Tedavi edilen 8 hastada (%21,6) göz içi basınç artışı görüldü. Sonuç: SRVT ve RVDT’na ikincil maküler ödem olgularında intravitreal dexametazon implant, ilk 6 ayda anatomik ve fonksiyonel düzelme sağlamıştır. Göz içi basıncı artışı dışında yan etki görülmemiştir.
Introduction: To evaluate the six-month effect and side effects of dexamethasone implant in the treatment of central retinal vein occlusion (SRVT) and retinal vein branch occlusion (RVDT) induced macular edema (MO). Material and Method: Thirty-seven patients (37 eyes) who were treated with intravitreal dexamethasone implant due to SRVT (n = 19) and RVDT(n = 18) in the Ophthalmology Department were included in the study. Records of patients were reviewed retrospectively. Patients who were followed up monthly for at least 6 months were included in the study. It was performed at the beginning and after each treatment; slit-lamp biomicroscopic examination findings, best corrected visual acuity (EDGK), spectral domain optical coherence tomography (OKT) and central macular thickness (SMK) measurements were done and side effects were recorded. Results: The patients were divided into two groups: RVDT group 1 (n = 18), SRVT group 2 (n = 19). In all patients, after the treatment, EDGK increased significantly up to the 4th month, whereas the values of SMK decreased significantly (p<0.05). There was no significant difference between EDGK after the 4th month. The increase in maximum visual acuity was significantly higher in group 1 than 2. There was no statistically significant difference between the two groups in terms of average SMK reduction (p>0.05). In 8 (21.6%) patients treated with intravitreal dexamethasone implant, intraocular pressure increased. Intravitreal dexamethasone implant provides anatomical and functional improvement in the first 6 months in patients with macular edema secondary to SRVT and RVDT. No side effects were seen except intraocular pressure.
Introduction: To evaluate the six-month effect and side effects of dexamethasone implant in the treatment of central retinal vein occlusion (SRVT) and retinal vein branch occlusion (RVDT) induced macular edema (MO). Material and Method: Thirtyseven patients (37 eyes) who were treated with intravitreal dexamethasone implant due to SRVT (n = 19) and RVDT(n = 18) in the Ophthalmology Department were included in the study. Records of patients were reviewed retrospectively. Patients who were followed up monthly for at least 6 months were included in the study. It was performed at the beginning and after each treatment; slit-lamp biomicroscopic examination findings, best corrected visual acuity (EDGK), spectral domain optical coherence tomography (OKT) and central macular thickness (SMK) measurements were done and side effects were recorded. Results: The patients were divided into two groups: RVDT group 1 (n = 18), SRVT group 2 (n = 19). In all patients, after the treatment, EDGK increased significantly up to the 4th month, whereas the values of SMK decreased significantly (p<0.05). There was no significant difference between EDGK after the 4th month. The increase in maximum visual acuity was significantly higher in group 1 than 2. There was no statistically significant difference between the two groups in terms of mean SMK reduction (p>0.05). In 8 (21.6%) patients treated with intravitreal dexamethasone implant, intraocular pressure increased. Discussion: Intravitreal dexamethasone implant provides anatomic and functional improvement in the first 6 months in patients with macular edema secondary to SRVT and RVDT. No side effects were seen except intraocular pressure.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
